Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Tharimmune, Inc. - Common Stock
(NQ:
THAR
)
0.3691
+0.0080 (+2.22%)
Streaming Delayed Price
Updated: 3:57 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
63,108
Open
0.3600
Bid (Size)
0.3700 (3)
Ask (Size)
0.3800 (5)
Prev. Close
0.3611
Today's Range
0.3584 - 0.3699
52wk Range
0.1434 - 4.790
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)
April 23, 2024
Via
ACCESSWIRE
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
April 15, 2024
Via
ACCESSWIRE
Performance
YTD
-26.90%
-26.90%
1 Month
-14.76%
-14.76%
3 Month
-20.96%
-20.96%
6 Month
+110.79%
+110.79%
1 Year
+67.70%
+67.70%
More News
Read More
Tharimmune to Present at the Emerging Growth Conference on March 7, 2024
March 05, 2024
Via
ACCESSWIRE
Tharimmune's Oral 'Under The Cheek' Candidate At Par With FDA-Approved Injectable With Potential For Chronic Liver Disease
February 20, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 20, 2024
Via
Benzinga
Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate
February 20, 2024
Via
ACCESSWIRE
Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update
January 29, 2024
Via
ACCESSWIRE
Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis
February 05, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Thursday's After-Market Session
January 25, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 24, 2024
Via
Benzinga
Perspective Therapeutics And 3 Other Stocks Under $1 Insiders Are Buying
December 19, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients
December 11, 2023
Via
ACCESSWIRE
Why Hello Group Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
December 08, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
December 07, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
December 04, 2023
Via
Benzinga
Tharimmune, Inc. Announces Closing of $11 Million Public Offering
November 30, 2023
Via
ACCESSWIRE
Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
November 30, 2023
Via
Newsfile
BioMedNewsBreaks – Tharimmune Inc. (NASDAQ: THAR) Announces Pricing of $10M Public Offering
November 29, 2023
Via
Investor Brand Network
Crude Oil Surges 2%; Tharimmune Shares Plummet
November 28, 2023
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
November 28, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
November 28, 2023
Via
Benzinga
Why Tharimmune Stock (THAR) Is Down 70% Today
November 28, 2023
Via
Benzinga
Shein IPO Alert: 7 Things for Potential Shein Stock Investors to Know
November 28, 2023
Via
InvestorPlace
Topics
Initial Public Offering
Exposures
Securities Market
US Stocks Mixed; House Prices Rise In September
November 28, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is SenesTech (SNES) Stock Down 36% Today?
November 28, 2023
Via
InvestorPlace
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.